CliffBio
small molecule

GALLIUM GA 68 EDOTREOTIDE

GALLIUM GA-68 EDOTREOTIDE

Loss of exclusivityAugust 2026FDA regulatory exclusivity expiry
CompanyUNIV IOWA HOSPS AND CLINICS PET IMAGING CENTER

Drug detail

Brand nameGALLIUM GA 68 EDOTREOTIDE
Active ingredientGALLIUM GA-68 EDOTREOTIDE
Strength0.5-4mCi/ML
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalAugust 2019
Marketing statusRX

Regulatory exclusivity

CodeExpires
ODE-383August 2026
WAugust 2026

More from UNIV IOWA HOSPS AND CLINICS PET IMAGING CENTER

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

GALLIUM GA 68 EDOTREOTIDE patent cliff — loss of exclusivity August 2026 | CliffBio